{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:32:18Z","timestamp":1790937138102,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,1,27]],"date-time":"2009-01-27T00:00:00Z","timestamp":1233014400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s11523-008-0099-0","type":"journal-article","created":{"date-parts":[[2009,1,26]],"date-time":"2009-01-26T09:02:10Z","timestamp":1232960530000},"page":"11-21","source":"Crossref","is-referenced-by-count":10,"title":["Targeted therapy for chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"4","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,1,27]]},"reference":[{"key":"99_CR1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2007-12-129379","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 111:4916\u20134921","journal-title":"Blood"},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990","volume":"87","author":"BD Cheson","year":"1996","unstructured":"Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990\u20137","journal-title":"Blood"},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H Dohner","year":"1995","unstructured":"Dohner H, Fischer K, Bentz M et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580\u20131589","journal-title":"Blood"},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A et al (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910\u20131916","journal-title":"N Engl J Med"},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435\u2013445","journal-title":"Blood"},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","volume":"181","author":"PV Beum","year":"2008","unstructured":"Beum PV, Lindorfer MA, Beurskens F et al (2008) Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 181:822\u2013832","journal-title":"J Immunol"},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","volume":"98","author":"J Golay","year":"2001","unstructured":"Golay J, Lazzari M, Facchinetti V et al (2001) CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 98:3383\u20133389","journal-title":"Blood"},{"key":"99_CR10","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","volume":"95","author":"J Golay","year":"2000","unstructured":"Golay J, Zaffaroni L, Vaccari T et al (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95:3900\u20133908","journal-title":"Blood"},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","volume":"24","author":"SP Treon","year":"2001","unstructured":"Treon SP, Mitsiades C, Mitsiades N et al (2001) Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 24:263\u2013271","journal-title":"J Immunother"},{"key":"99_CR12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","volume":"99","author":"IM Pedersen","year":"2002","unstructured":"Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J (2002) The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 99:1314\u20131319","journal-title":"Blood"},{"key":"99_CR13","first-page":"709","volume":"7","author":"S Alas","year":"2001","unstructured":"Alas S, Emmanouilides C, Bonavida B (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin\u2019s lymphoma to apoptosis. Clin Cancer Res 7:709\u2013723","journal-title":"Clin Cancer Res"},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","volume":"84","author":"DG Maloney","year":"1994","unstructured":"Maloney DG, Liles TM, Czerwinski DK et al (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457\u20132466","journal-title":"Blood"},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma. J Clin Oncol 15:3266\u20133274","journal-title":"J Clin Oncol"},{"key":"99_CR16","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"99_CR17","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825\u20132833","journal-title":"J Clin Oncol"},{"key":"99_CR18","first-page":"9","volume":"27","author":"AJ Grillo-Lopez","year":"2000","unstructured":"Grillo-Lopez AJ (2000) Rituximab: an insider\u2019s historical perspective. Semin Oncol 27:9\u201316","journal-title":"Semin Oncol"},{"key":"99_CR19","first-page":"1763","volume":"12","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12:1763\u20131769 discussion 1769\u20131770, 1775\u20131777","journal-title":"Oncology (Williston Park)"},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-0609.1999.tb01725.x","volume":"62","author":"DT Nguyen","year":"1999","unstructured":"Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW (1999) IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin\u2019s lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 62:76\u201382","journal-title":"Eur J Haematol"},{"key":"99_CR21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","volume":"94","author":"U Winkler","year":"1999","unstructured":"Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94:2217\u20132224","journal-title":"Blood"},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02780529","volume":"17","author":"M Ladetto","year":"2000","unstructured":"Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C (2000) Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Med Oncol 17:203\u2013210","journal-title":"Med Oncol"},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V98.5.1326","volume":"98","author":"D Huhn","year":"2001","unstructured":"Huhn D, von Schilling C, Wilhelm M et al (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326\u20131331","journal-title":"Blood"},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0609.2002.02786.x","volume":"69","author":"M Itala","year":"2002","unstructured":"Itala M, Geisler CH, Kimby E et al (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 69:129\u2013134","journal-title":"Eur J Haematol"},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2003.09.027","volume":"21","author":"JD Hainsworth","year":"2003","unstructured":"Hainsworth JD, Litchy S, Barton JH et al (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21:1746\u20131751","journal-title":"J Clin Oncol"},{"key":"99_CR26","first-page":"364","volume":"98","author":"D Thomas","year":"2001","unstructured":"Thomas D, O\u2019Brien S, Giles FJ et al (2001) Single agent rituxan in early stage chronic lymphocytic leukemia (CLL). Blood 98:364","journal-title":"Blood"},{"key":"99_CR27","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O\u2019Brien","year":"2001","unstructured":"O\u2019Brien SM, Kantarjian H, Thomas DA et al (2001) Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19:2165\u20132170","journal-title":"J Clin Oncol"},{"key":"99_CR28","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1200\/JCO.2001.19.8.2153","volume":"19","author":"JC Byrd","year":"2001","unstructured":"Byrd JC, Murphy T, Howard RS et al (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19:2153\u20132164","journal-title":"J Clin Oncol"},{"key":"99_CR29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","volume":"101","author":"JC Byrd","year":"2003","unstructured":"Byrd JC, Peterson BL, Morrison VA et al (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6\u201314","journal-title":"Blood"},{"key":"99_CR30","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","volume":"23","author":"W Wierda","year":"2005","unstructured":"Wierda W, O\u2019Brien S, Wen S et al (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070\u20134078","journal-title":"J Clin Oncol"},{"key":"99_CR31","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","volume":"23","author":"MJ Keating","year":"2005","unstructured":"Keating MJ, O\u2019Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079\u20134088","journal-title":"J Clin Oncol"},{"key":"99_CR32","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975\u2013980","journal-title":"Blood"},{"key":"99_CR33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.2005.04.3836","volume":"24","author":"N Lamanna","year":"2006","unstructured":"Lamanna N, Kalaycio M, Maslak P et al (2006) Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 24:1575\u20131781","journal-title":"J Clin Oncol"},{"key":"99_CR34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2006-07-033274","volume":"109","author":"NE Kay","year":"2007","unstructured":"Kay NE, Geyer SM, Call TG et al (2007) Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 109:405\u2013411","journal-title":"Blood"},{"key":"99_CR35","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","volume":"62","author":"G Hale","year":"1983","unstructured":"Hale G, Bright S, Chumbley G et al (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873\u2013882","journal-title":"Blood"},{"key":"99_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.1985.tb07383.x","volume":"60","author":"G Hale","year":"1985","unstructured":"Hale G, Swirsky D, Waldmann H, Chan LC (1985) Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation. Br J Haematol 60:41\u201348","journal-title":"Br J Haematol"},{"key":"99_CR37","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/eji.1830210714","volume":"21","author":"MQ Xia","year":"1991","unstructured":"Xia MQ, Tone M, Packman L, Hale G, Waldmann H (1991) Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 21:1677\u20131684","journal-title":"Eur J Immunol"},{"key":"99_CR38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"MH Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807\u2013812","journal-title":"Blood"},{"key":"99_CR39","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2567.1998.00615.x","volume":"95","author":"W Rowan","year":"1998","unstructured":"Rowan W, Tite J, Topley P, Brett SJ (1998) Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95:427\u2013436","journal-title":"Immunology"},{"key":"99_CR40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x","volume":"96","author":"AL Bowen","year":"1997","unstructured":"Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D (1997) Subcutaneous CAMPATH-1H in fludarabine-resistant\/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617\u2013619","journal-title":"Br J Haematol"},{"key":"99_CR41","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et al (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554\u20133561","journal-title":"Blood"},{"key":"99_CR42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151\u2013153","journal-title":"Br J Haematol"},{"key":"99_CR43","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D et al (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15:1567\u20131574","journal-title":"J Clin Oncol"},{"key":"99_CR44","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","volume":"20","author":"KR Rai","year":"2002","unstructured":"Rai KR, Freter CE, Mercier RJ et al (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 20:3891\u20133897","journal-title":"J Clin Oncol"},{"key":"99_CR45","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S WD, Krober A, et al. (2004) Subcutaneous campath-1H (alemtuzumab) in fludarabine-refractory cll: interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG). Blood 104:(abstract 478)","DOI":"10.1182\/blood.V104.11.478.478"},{"key":"99_CR46","doi-asserted-by":"crossref","unstructured":"Montillo M TA, Rossi V, et al. (2004) Alemtuzumab as consolidation after a response to fludarabine is effective to purge residual disease in patients with chronic lymphocytic leukemia. Blood 104:(abstract 479)","DOI":"10.1182\/blood.V104.11.479.479"},{"key":"99_CR47","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G et al (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23:2971\u20132979","journal-title":"J Clin Oncol"},{"key":"99_CR48","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","volume":"347","author":"S Stilgenbauer","year":"2002","unstructured":"Stilgenbauer S, Dohner H (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347:452\u2013453","journal-title":"N Engl J Med"},{"key":"99_CR49","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","volume":"25","author":"P Hillmen","year":"2007","unstructured":"Hillmen P, Skotnicki AB, Robak T et al (2007) Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 25:5616\u20135623","journal-title":"J Clin Oncol"},{"key":"99_CR50","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1200\/JCO.2005.01.9950","volume":"23","author":"T Elter","year":"2005","unstructured":"Elter T, Borchmann P, Schulz H et al (2005) Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23:7024\u20137031","journal-title":"J Clin Oncol"},{"key":"99_CR51","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.14.14","volume":"108","author":"W Wierda","year":"2006","unstructured":"Wierda W, O\u2019Brien S, Faderl S et al (2006) Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL. Blood 108:14a","journal-title":"Blood"},{"key":"99_CR52","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","volume":"98","author":"SM O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SM, Kantarjian HM, Thomas DA et al (2003) Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98:2657\u20132663","journal-title":"Cancer"},{"key":"99_CR53","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.leu.2403354","volume":"18","author":"CM Wendtner","year":"2004","unstructured":"Wendtner CM, Ritgen M, Schweighofer CD et al (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission\u2014experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18:1093\u20131101","journal-title":"Leukemia"},{"key":"99_CR54","unstructured":"Rai K, Byrd, JC, Peterson, B, et al. (2003) Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 1990. Blood 102:(abstract 2506)."},{"key":"99_CR55","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1200\/JCO.2005.04.6037","volume":"24","author":"M Montillo","year":"2006","unstructured":"Montillo M, Tedeschi A, Miqueleiz S et al (2006) Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24:2337\u20132342","journal-title":"J Clin Oncol"},{"key":"99_CR56","doi-asserted-by":"crossref","unstructured":"Lin TS, Donohue KA, Lucas MS, et al. (2007) Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 110:(abstract 755)","DOI":"10.1182\/blood.V110.11.755.755"},{"key":"99_CR57","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","volume":"101","author":"S Faderl","year":"2003","unstructured":"Faderl S, Thomas DA, O\u2019Brien S et al (2003) Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101:3413\u20133415","journal-title":"Blood"},{"key":"99_CR58","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","volume":"113","author":"CS Zent","year":"2008","unstructured":"Zent CS, Call TG, Shanafelt TD et al (2008) Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 113:2110\u20132118","journal-title":"Cancer"},{"key":"99_CR59","first-page":"438a","volume":"102","author":"NZA Pathan","year":"2003","unstructured":"Pathan NZA, Wynne D et al (2003) Lumiliximab (IDEC-152) an anti-CD23 antibody, induces apoptosis in vitro and in vivo in CLL cells. Blood 102:438a","journal-title":"Blood"},{"key":"99_CR60","first-page":"393a","volume":"11","author":"M Mangiola","year":"2004","unstructured":"Mangiola M, Welsh K, Kitada S et al (2004) Anti-CD20 antibody rituximab and anti-CD23 antibody IDEC-152 induce apoptosis of malignant B-cells in combination with chemical antagonists of XIAP. Blood 11:393a","journal-title":"Blood"},{"key":"99_CR61","unstructured":"Pathan N, Hopkins M, Saven A, et al. (2001) Induction of apoptosis by IDEC-152 (anti-CD23) in chronic lymphocytic leukemia. Leuk Lymphoma 42"},{"key":"99_CR62","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1158\/1078-0432.CCR-06-1463","volume":"13","author":"JC Byrd","year":"2007","unstructured":"Byrd JC, O\u2019Brien S, Flinn IW et al (2007) Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 13:4448\u20134455","journal-title":"Clin Cancer Res"},{"key":"99_CR63","first-page":"14a","volume":"11","author":"J Byrd","year":"2006","unstructured":"Byrd J, Castro J, O\u2019Brien S et al (2006) Comparison of results from a phase 1\/2 study of lumiliximab (anti-CD23) in combination with FCR for patients with relapsed CLL with published FCR results. Blood 11:14a","journal-title":"Blood"},{"key":"99_CR64","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","volume":"177","author":"JL Teeling","year":"2006","unstructured":"Teeling JL, Mackus WJ, Wiegman LJ et al (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177:362\u2013371","journal-title":"J Immunol"},{"key":"99_CR65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","volume":"104","author":"JL Teeling","year":"2004","unstructured":"Teeling JL, French RR, Cragg MS et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793\u20131800","journal-title":"Blood"},{"key":"99_CR66","doi-asserted-by":"crossref","unstructured":"Coiffier B, Tilly H, Pedersen LM, et al. (2006) Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 11:(abstract 2842)","DOI":"10.1182\/blood.V108.11.2842.2842"},{"key":"99_CR67","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1182\/blood-2006-04-020057","volume":"108","author":"JA Bowles","year":"2006","unstructured":"Bowles JA, Wang SY, Link BK et al (2006) Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108:2648\u20132654","journal-title":"Blood"},{"key":"99_CR68","doi-asserted-by":"crossref","unstructured":"Umana P, Ekkehard M, Bruenker P, et al. (2006) Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 11:(abstract 229)","DOI":"10.1182\/blood.V108.11.229.229"},{"key":"99_CR69","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1158\/1078-0432.CCR-03-0493","volume":"10","author":"R Stein","year":"2004","unstructured":"Stein R, Qu Z, Chen S et al (2004) Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin\u2019s lymphoma. Clin Cancer Res 10:2868\u20132878","journal-title":"Clin Cancer Res"},{"key":"99_CR70","doi-asserted-by":"crossref","unstructured":"Morshhauser F, Leonard JP, Coiffier B, et al. (2006) Phase I\/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL. Proc Am Soc Clin Oncol 24:(abstract 7530)","DOI":"10.1200\/jco.2006.24.18_suppl.7530"},{"key":"99_CR71","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.2003.01.082","volume":"21","author":"JP Leonard","year":"2003","unstructured":"Leonard JP, Coleman M, Ketas JC et al (2003) Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol 21:3051\u20133059","journal-title":"J Clin Oncol"},{"key":"99_CR72","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1200\/JCO.2005.13.821","volume":"23","author":"JP Leonard","year":"2005","unstructured":"Leonard JP, Coleman M, Ketas J et al (2005) Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:5044\u20135051","journal-title":"J Clin Oncol"},{"key":"99_CR73","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.1366","volume":"93","author":"SA Kostelny","year":"2001","unstructured":"Kostelny SA, Link BK, Tso JY et al (2001) Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 93:556\u2013565","journal-title":"Int J Cancer"},{"key":"99_CR74","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood-2007-08-110072","volume":"111","author":"Z Qu","year":"2008","unstructured":"Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH (2008) Bispecific anti-CD20\/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 111:2211\u20132219","journal-title":"Blood"},{"key":"99_CR75","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","volume":"321","author":"R Bargou","year":"2008","unstructured":"Bargou R, Leo E, Zugmaier G et al (2008) Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321:974\u2013977","journal-title":"Science"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-008-0099-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-008-0099-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-008-0099-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:51:50Z","timestamp":1589507510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-008-0099-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,27]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11523-008-0099-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,27]]}}}